阿帕替尼治疗晚期结直肠癌疗效及安全性  

Efficacy and Safety of Apatinib in Treating Advanced Colorectal Cancer

作　　者：李宁宁[1] 周建凤[1] 赵林[1] 应红艳[1] 贾宁[1] LI Ningning;ZHOU Jianfeng;ZHAO Lin;YING Hongyan;JIA Ning(Department of Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100032,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院肿瘤内科

出　　处：《中国医学科学院学报》2019年第2期170-174,共5页Acta Academiae Medicinae Sinicae

摘　　要：目的观察阿帕替尼在晚期结直肠癌中的疗效及安全性。方法 回顾性分析16例应用阿帕替尼治疗的既往多线治疗失败的转移性结直肠癌患者的临床资料,分析其客观有效率、疾病控制率、无进展生存期、总生存期;评价其不良反应发生率;探索其预后因素。结果 14例患者可评价疗效,客观有效率7.1%,疾病控制率50%,中位无进展生存期3个月(95%CI=1.57~4.42),中位总生存期6.5个月(95%CI=4.10~8.89)。16例患者评价不良反应,3级不良反应包括:高血压(37.5%)、蛋白尿(25%)。无4级不良反应。多因素分析未显示出有统计学差异的与生存相关的因素。结论 晚期结直肠癌患者应用阿帕替尼治疗,可能有一定疗效,且不良反应可耐受,值得进一步研究。Objective To assess the efficacy and safety of apatinib in the treatment of advanced colorectal cancer(CRC). Methods The clinical data of 16 CRC patients treated with apatinib after failure of prior lines of treatment were retrospectively analyzed in terms of objective response rate,disease control rate,progression-free survival,overall survival,adverse events,and prognostic factors. Results The efficacy was evaluable in 14 patients,among whom the objective response rate was 7.1% and the disease control rate was 50%.The median progression-free survival was 3 months(95% CI =1.57-4.42),and the median overall survival was 6.5 months(95% CI =4.10-8.89).The safety was evaluable in 16 patients,among whom the most common grade 3 adverse events were hypertensinon(37.5%)and proteinuria(25%).No grade 4 adverse event was observed.Multivariate analysis did not show any factor directly related to survival. Conclusion Apatinib may be effective in treating advanced CRC,with tolerable side effects.

关 键 词：阿帕替尼 晚期结直肠癌 血管内皮生长因子受体 

分 类 号：R735.5[医药卫生—肿瘤]